Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAN phase 3 trial of apremilast in pediatric Behçet's disease with active oral ulcers
2019-002787-27Phase 3Active
- Sponsor
- Amgen
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Behçet's disease (BD) comparing Apremilast with Placebo (2 arms). Primary endpoint: Area under the curve for the number of oral ulcers. Started Dec 2020; status: active.
02
Drugs
apremilast
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on 2019-002787-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002787-27.